Arizona 2023 Regular Session

Arizona House Bill HB2245 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	REFERENCE TITLE: generic prescription drugs; manufacturing State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023 HB 2245 Introduced by Representatives De Los Santos: Aguilar, Mathis, Ortiz, Sandoval, Stahl Hamilton, Terech, Travers An Act amending title 36, Arizona Revised Statutes, by adding chapter 42; relating to drug manufacturing. (TEXT OF BILL BEGINS ON NEXT PAGE)
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9	REFERENCE TITLE: generic prescription drugs; manufacturing
10	10	State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023
11	11	HB 2245
12	12	Introduced by Representatives De Los Santos: Aguilar, Mathis, Ortiz, Sandoval, Stahl Hamilton, Terech, Travers
13	13
14	14	REFERENCE TITLE: generic prescription drugs; manufacturing
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24	State of Arizona
25	25
26	26	House of Representatives
27	27
28	28	Fifty-sixth Legislature
29	29
30	30	First Regular Session
31	31
32	32	2023
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40	HB 2245
41	41
42	42
43	43
44	44	Introduced by
45	45
46	46	Representatives De Los Santos: Aguilar, Mathis, Ortiz, Sandoval, Stahl Hamilton, Terech, Travers
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64	An Act
65	65
66	66
67	67
68	68	amending title 36, Arizona Revised Statutes, by adding chapter 42; relating to drug manufacturing.
69	69
70	70
71	71
72	72
73	73
74	74	(TEXT OF BILL BEGINS ON NEXT PAGE)
75	75
76	76
77	77
78	78	Be it enacted by the Legislature of the State of Arizona: Section 1. Title 36, Arizona Revised Statutes, is amended by adding chapter 42, to read: CHAPTER 42 ARIZONA AFFORDABLE DRUG MANUFACTURING ARTICLE 1. GENERAL PROVISIONS START_STATUTE36-4201. Definitions In this chapter, unless the context otherwise requires: 1. "Department" means the department of health services. 2. "Generic prescription drug" means a drug that is approved pursuant to section 355, subsection (j) of the federal food, drug, and cosmetic act or a biosimilar, as defined under the public health service act (42 United States Code section 262). 3. "Partnership" includes agreements to procure generic prescription drugs by way of contracts or purchasing by a payor, state governmental agency, group purchasing organization, nonprofit organization or other entity. 4. "Provider" means a hospital, a skilled nursing facility, an outpatient rehabilitation facility, a home health agency, a hospice or a clinic. 5. "Supplier": (a) Means a physician, surgeon or other health care provider. (b) Includes an entity that furnishes health care services other than a health care provider.END_STATUTE START_STATUTE36-4202. Partnerships; prescription drugs; project management A. The department shall enter into partnerships, consistent with section 36-4203 in consultation with other state departments as necessary, to increase competition, lower prices and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers and consumers and to increase patient access to affordable drugs. B. The department may hire staff to oversee and project-manage the partnerships for manufacturing or distributing generic prescription drugs, contingent on a legislative appropriation for this purpose.END_STATUTE START_STATUTE36-4203. Partnerships; generic prescription drugs; priority; consultation A. The department shall enter into partnerships resulting in the production or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers and pharmacies, as appropriate. The generic prescription drugs shall be produced or distributed by a drug company or generic drug manufacturer that is registered with the United States food and drug administration. B. The department may enter into partnerships pursuant to subsection A of this section only to produce a generic prescription drug at a price that results in savings, targets failures in the market for generic prescription drugs and improves patient access to affordable medications. For top drugs prioritized pursuant to subsection D of this section, the department shall determine whether viable pathways exist for partnerships to manufacture or distribute generic prescription drugs by examining the relevant legal, market, policy and regulatory factors. C. The department shall consider the following, if applicable, when setting the price of the generic prescription drug: 1. United States food and drug administration user fees. 2. Abbreviated new drug application acquisition costs amortized over a five-year period. 3. Mandatory rebates. 4. Total contracting and production costs for the drug, including a reasonable amount for administrative, operating and rate-of-return expenses of the drug company or generic drug manufacturer. 5. Research and development costs attributed to the drug over a five-year period. 6. Other initial start-up costs amortized over a five-year period. D. Each drug shall be made available to health care providers, patients and purchasers at a transparent price and without rebates, other than federally required rebates. The department shall prioritize the selection of generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health or reducing the cost of prescription drugs to public and private purchasers. E. In identifying generic prescription drugs to be produced, The department shall consider pharmacy spending data from the Arizona health care cost containment system and other entities for which the state pays the cost of generic prescription drugs. F. The partnerships entered into pursuant to subsection A of this section shall include the production of at least one form of insulin if a viable pathway for manufacturing a more affordable form of insulin exists. The department shall prioritize drugs for chronic and high-cost conditions and shall consider prioritizing those that can be delivered through mail order. G. The department shall consult with all of the following public and private purchasers to assist in developing a list of generic prescription drugs to be manufactured or distributed through partnerships and to determine the volume of each generic prescription drug that can be procured over a multiyear period to support a market for lower-cost generic prescription drugs: 1. The Arizona health care cost containment administration, the Arizona state retirement system, the department of administration and the state department of corrections, or the entities acting on behalf of each of those state purchasers. 2. Health insurers. 3. Hospitals. 4. Pharmacy benefit managers. H. Before entering into a partnership pursuant to this section, the department shall determine minimum thresholds for procuring an entity's expected volume of a targeted drug from the company or manufacturer over a multiyear period. I. The entities listed in subsection G, paragraphs 2, 3 and 4 of this section are not required to purchase prescription drugs from the department or entities that contract or partner with the department pursuant to this chapter. The department is not required to consult with each of the entities listed in subsection G, paragraphs 2, 3 and 4 of this section if the purchaser engagement includes a reasonable representation from these groups.END_STATUTE START_STATUTE36-4204. Reports A. For the purposes of this chapter, subject to legislative appropriations: 1. On or before July 1, 2025, the department shall submit a report to the governor, the speaker of the house of representatives and the president of the senate on both of the following: (a) A description of the status of all drugs targeted under this chapter. (b) An analysis of how the activities of the department may impact competition, access to targeted drugs, the costs of those drugs and the costs of generic prescription drugs to public and private purchasers. 2. On or before July 1, 2026, the department shall submit a report to the governor, the speaker of the house of representatives and the president of the senate that assesses the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price. The report shall include an analysis of governance structure options for manufacturing functions, including chartering a private organization, a public-private partnership or a public board of directors. B. A copy of each of the reports submitted pursuant subsection A of this section shall be sent to the secretary of state.END_STATUTE START_STATUTE36-4205. Confidential information; public records exemption In order to protect proprietary, confidential information regarding manufacturer or distribution costs and drug pricing, utilization and rebates, it is necessary that this act limit the public's right of access to that information. Notwithstanding any other provision of law, all nonpublic information and documents obtained pursuant to this chapter are confidential and are not public records and are not subject to title 39, chapter 1, article 2.END_STATUTE
79	79
80	80	Be it enacted by the Legislature of the State of Arizona:
81	81
82	82	Section 1. Title 36, Arizona Revised Statutes, is amended by adding chapter 42, to read:
83	83
84	84	CHAPTER 42
85	85
86	86	ARIZONA AFFORDABLE DRUG MANUFACTURING
87	87
88	88	ARTICLE 1. GENERAL PROVISIONS
89	89
90	90	START_STATUTE36-4201. Definitions
91	91
92	92	In this chapter, unless the context otherwise requires:
93	93
94	94	1. "Department" means the department of health services.
95	95
96	96	2. "Generic prescription drug" means a drug that is approved pursuant to section 355, subsection (j) of the federal food, drug, and cosmetic act or a biosimilar, as defined under the public health service act (42 United States Code section 262).
97	97
98	98	3. "Partnership" includes agreements to procure generic prescription drugs by way of contracts or purchasing by a payor, state governmental agency, group purchasing organization, nonprofit organization or other entity.
99	99
100	100	4. "Provider" means a hospital, a skilled nursing facility, an outpatient rehabilitation facility, a home health agency, a hospice or a clinic.
101	101
102	102	5. "Supplier":
103	103
104	104	(a) Means a physician, surgeon or other health care provider.
105	105
106	106	(b) Includes an entity that furnishes health care services other than a health care provider.END_STATUTE
107	107
108	108	START_STATUTE36-4202. Partnerships; prescription drugs; project management
109	109
110	110	A. The department shall enter into partnerships, consistent with section 36-4203 in consultation with other state departments as necessary, to increase competition, lower prices and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers and consumers and to increase patient access to affordable drugs.
111	111
112	112	B. The department may hire staff to oversee and project-manage the partnerships for manufacturing or distributing generic prescription drugs, contingent on a legislative appropriation for this purpose.END_STATUTE
113	113
114	114	START_STATUTE36-4203. Partnerships; generic prescription drugs; priority; consultation
115	115
116	116	A. The department shall enter into partnerships resulting in the production or distribution of generic prescription drugs, with the intent that these drugs be made widely available to public and private purchasers, providers and suppliers and pharmacies, as appropriate. The generic prescription drugs shall be produced or distributed by a drug company or generic drug manufacturer that is registered with the United States food and drug administration.
117	117
118	118	B. The department may enter into partnerships pursuant to subsection A of this section only to produce a generic prescription drug at a price that results in savings, targets failures in the market for generic prescription drugs and improves patient access to affordable medications. For top drugs prioritized pursuant to subsection D of this section, the department shall determine whether viable pathways exist for partnerships to manufacture or distribute generic prescription drugs by examining the relevant legal, market, policy and regulatory factors.
119	119
120	120	C. The department shall consider the following, if applicable, when setting the price of the generic prescription drug:
121	121
122	122	1. United States food and drug administration user fees.
123	123
124	124	2. Abbreviated new drug application acquisition costs amortized over a five-year period.
125	125
126	126	3. Mandatory rebates.
127	127
128	128	4. Total contracting and production costs for the drug, including a reasonable amount for administrative, operating and rate-of-return expenses of the drug company or generic drug manufacturer.
129	129
130	130	5. Research and development costs attributed to the drug over a five-year period.
131	131
132	132	6. Other initial start-up costs amortized over a five-year period.
133	133
134	134	D. Each drug shall be made available to health care providers, patients and purchasers at a transparent price and without rebates, other than federally required rebates. The department shall prioritize the selection of generic prescription drugs that have the greatest impact on lowering drug costs to patients, increasing competition and addressing shortages in the prescription drug market, improving public health or reducing the cost of prescription drugs to public and private purchasers.
135	135
136	136	E. In identifying generic prescription drugs to be produced, The department shall consider pharmacy spending data from the Arizona health care cost containment system and other entities for which the state pays the cost of generic prescription drugs.
137	137
138	138	F. The partnerships entered into pursuant to subsection A of this section shall include the production of at least one form of insulin if a viable pathway for manufacturing a more affordable form of insulin exists. The department shall prioritize drugs for chronic and high-cost conditions and shall consider prioritizing those that can be delivered through mail order.
139	139
140	140	G. The department shall consult with all of the following public and private purchasers to assist in developing a list of generic prescription drugs to be manufactured or distributed through partnerships and to determine the volume of each generic prescription drug that can be procured over a multiyear period to support a market for lower-cost generic prescription drugs:
141	141
142	142	1. The Arizona health care cost containment administration, the Arizona state retirement system, the department of administration and the state department of corrections, or the entities acting on behalf of each of those state purchasers.
143	143
144	144	2. Health insurers.
145	145
146	146	3. Hospitals.
147	147
148	148	4. Pharmacy benefit managers.
149	149
150	150	H. Before entering into a partnership pursuant to this section, the department shall determine minimum thresholds for procuring an entity's expected volume of a targeted drug from the company or manufacturer over a multiyear period.
151	151
152	152	I. The entities listed in subsection G, paragraphs 2, 3 and 4 of this section are not required to purchase prescription drugs from the department or entities that contract or partner with the department pursuant to this chapter. The department is not required to consult with each of the entities listed in subsection G, paragraphs 2, 3 and 4 of this section if the purchaser engagement includes a reasonable representation from these groups.END_STATUTE
153	153
154	154	START_STATUTE36-4204. Reports
155	155
156	156	A. For the purposes of this chapter, subject to legislative appropriations:
157	157
158	158	1. On or before July 1, 2025, the department shall submit a report to the governor, the speaker of the house of representatives and the president of the senate on both of the following:
159	159
160	160	(a) A description of the status of all drugs targeted under this chapter.
161	161
162	162	(b) An analysis of how the activities of the department may impact competition, access to targeted drugs, the costs of those drugs and the costs of generic prescription drugs to public and private purchasers.
163	163
164	164	2. On or before July 1, 2026, the department shall submit a report to the governor, the speaker of the house of representatives and the president of the senate that assesses the feasibility of directly manufacturing generic prescription drugs and selling generic prescription drugs at a fair price. The report shall include an analysis of governance structure options for manufacturing functions, including chartering a private organization, a public-private partnership or a public board of directors.
165	165
166	166	B. A copy of each of the reports submitted pursuant subsection A of this section shall be sent to the secretary of state.END_STATUTE
167	167
168	168	START_STATUTE36-4205. Confidential information; public records exemption
169	169
170	170	In order to protect proprietary, confidential information regarding manufacturer or distribution costs and drug pricing, utilization and rebates, it is necessary that this act limit the public's right of access to that information. Notwithstanding any other provision of law, all nonpublic information and documents obtained pursuant to this chapter are confidential and are not public records and are not subject to title 39, chapter 1, article 2.END_STATUTE